You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

ESCLIM Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Esclim patents expire, and when can generic versions of Esclim launch?

Esclim is a drug marketed by Women First Hlthcare and is included in one NDA.

The generic ingredient in ESCLIM is estradiol. There are seventy-five drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the estradiol profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Esclim

A generic version of ESCLIM was approved as estradiol by BARR LABS INC on October 22nd, 1997.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ESCLIM?
  • What are the global sales for ESCLIM?
  • What is Average Wholesale Price for ESCLIM?
Summary for ESCLIM
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 109
Patent Applications: 4,130
DailyMed Link:ESCLIM at DailyMed
Drug patent expirations by year for ESCLIM

US Patents and Regulatory Information for ESCLIM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Women First Hlthcare ESCLIM estradiol SYSTEM;TRANSDERMAL 020847-001 Aug 4, 1998 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Women First Hlthcare ESCLIM estradiol SYSTEM;TRANSDERMAL 020847-004 Aug 4, 1998 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Women First Hlthcare ESCLIM estradiol SYSTEM;TRANSDERMAL 020847-002 Aug 4, 1998 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Women First Hlthcare ESCLIM estradiol SYSTEM;TRANSDERMAL 020847-003 Aug 4, 1998 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Women First Hlthcare ESCLIM estradiol SYSTEM;TRANSDERMAL 020847-005 Aug 4, 1998 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ESCLIM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Women First Hlthcare ESCLIM estradiol SYSTEM;TRANSDERMAL 020847-001 Aug 4, 1998 ⤷  Sign Up ⤷  Sign Up
Women First Hlthcare ESCLIM estradiol SYSTEM;TRANSDERMAL 020847-004 Aug 4, 1998 ⤷  Sign Up ⤷  Sign Up
Women First Hlthcare ESCLIM estradiol SYSTEM;TRANSDERMAL 020847-005 Aug 4, 1998 ⤷  Sign Up ⤷  Sign Up
Women First Hlthcare ESCLIM estradiol SYSTEM;TRANSDERMAL 020847-003 Aug 4, 1998 ⤷  Sign Up ⤷  Sign Up
Women First Hlthcare ESCLIM estradiol SYSTEM;TRANSDERMAL 020847-002 Aug 4, 1998 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ESCLIM

See the table below for patents covering ESCLIM around the world.

Country Patent Number Title Estimated Expiration
Japan S63255217 ADHESIVE MATRIX FOR TRANSDERMAL ADMINISTRATION OF ACTIVE COMPONENT AND MANUFACTURE ⤷  Sign Up
France 2612785 ⤷  Sign Up
Germany 3866408 ⤷  Sign Up
Portugal 87029 PROCESSO PARA A PREPARACAO DE UM DISPOSITIVO AUTO-ADESIVO PARA ADMINISTRACAO DE UM PRINCIPIO ACTIVO POR VIA PERCUTANEA ⤷  Sign Up
European Patent Office 0288336 SELF-STICKING DEVICE FOR THE TRANSDERMAL ADMINISTRATION OF AN ACTIVE AGENT ⤷  Sign Up
Austria 69724 ⤷  Sign Up
Greece 3003887 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ESCLIM

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1380301 CA 2009 00017 Denmark ⤷  Sign Up PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629
2782584 132021000000197 Italy ⤷  Sign Up PRODUCT NAME: ESTRADIOLO (17SS-ESTRADIOLO) IN PARTICOLARE NELLA FORMA EMIIDRATA, E PROGESTERONE COMPRENDENTI LE VARIE FORME DI ESTRADIOLO (17SS-ESTRADIOLO), QUALI LE FORME IDRATE E SOLVATATE, INCLUDENDO LA FORMA EMIIDRATA, ED I SUOI SALI.(BIJUVA); AUTHORISATION NUMBER(S) AND DATE(S): BE582231, 20210406;048335018 -048335020, 20210517
1380301 2009C/007 Belgium ⤷  Sign Up PRODUCT NAME: DROSPIRENONE-ETHINYLESTRADIOL; AUTHORISATION NUMBER AND DATE: BE321386 20080811
1214076 49/2008 Austria ⤷  Sign Up PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON; REGISTRATION NO/DATE: 1-27586 20080612
1214076 SZ 49/2008 Austria ⤷  Sign Up PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON
0770388 2009/012 Ireland ⤷  Sign Up PRODUCT NAME: QLAIRA-ESTRADIOL VALERATE/DIENOGEST; NAT REGISTRATION NO/DATE: PA1410/58/1 20090109; FIRST REGISTRATION NO/DATE: BE327792 20081103
0770388 09C0018 France ⤷  Sign Up PRODUCT NAME: ESTRADIOL VALERATE; DIENOGEST; NAT. REGISTRATION NO/DATE: NL35170 20081210; FIRST REGISTRATION: BE327792 20081103
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.